A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

Clinical trial NCT02454270 · TERMINATED

Trial details

NCT number: NCT02454270
Sponsor: Janssen Research & Development, LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Lymphoma, Mantle-Cell Precursor Cell Lymphoblastic Leukemia-Lymphoma

Start date: 2015-06-15
Primary completion: 2018-07-26
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.